Regenics AS completes second tranche of private placement to continue development of Collex®

"We are excited that Nordic Blue with their experience and success in the field of wound care continue to believe and are willing to support Regenics in the further development of Collex®," said Jan A. Alfheim, Board Chair of Regenics. "Their investment and participation at the board level have been of great value this past year and we look forward to continuing our successful collaboration." "We are excited that Nordic Blue with their experience and success in the field of wound care continue...

"We are excited that Nordic Blue with their experience and success in the field of wound care continue to believe and are willing to support Regenics in the further development of Collex®," said Jan A. Alfheim, Board Chair of Regenics. "Their investment and participation at the board level have been of great value this past year and we look forward to continuing our successful collaboration."

Brynjolfur Eyjolfsson, Fund Manager, Haf Investments and chairman of Nordic Blue hf. commented, 

"We continue to see tremendous potential in Regenics and its wound care products. Collex® represents an effective and sustainable approach to wound care, and we are proud to continue supporting its development. With Regenics' strong scientific foundation and clear clinical focus, we believe the company is well-positioned to make a meaningful impact in the wound care market. Our increased investment reflects our confidence in the team and in the broader vision of building value through marine-based biotech innovation."

About Collex®

Collex® is an advanced wound dressing designed to aid healing of partial thickness burns and chronic wounds, including diabetic and chronic vascular ulcers. With Collex®, Regenics aims to redefine the current standards of care in wound treatment.

Collex® is a hydrogel wound dressing constructed with all-marine ingredients, sourced from the Norwegian coast. One of Regenics' major innovations, HTX™, is an essential component of Collex® and is sourced and purified from unfertilized salmon roe. Collex® is currently in the late pre-clinical stage, with significant beneficial effects on wound healing rates demonstrated.

About Nordic Blue

Nordic Blue Is an Icelandic holding company focusing on investments in Blue Economy, with versatile shareholders, with many of the investors having a background in marine biotechnology, pharmaceuticals and fisheries.

About Haf Investments

Haf Investments (IS Haf Fjárfestingar slhf.) invests in unlisted companies across the seafood value chain and in supporting industries. The investment strategy covers five categories, from fishing and aquaculture to high technology, infrastructure development, marketing and marine biotechnology. The largest investors in the fund are Icelandic pension funds together with UR Seafood (Útgerðarfélag Reykjavíkur hf.), which is a cornerstone investor in the fund, and Brim hf. The fund is managed Iceland Funds hf., which is the first and one of the largest Icelandic fund management companies, established in 1994. It is a wholly owned subsidiary of Íslandsbanki and is supervised by the Icelandic Financial Supervisory Authority (FME). The company provides investments offering for individuals, companies, municipalities, pension funds and other institutional investors.

For further information, please contact:

Jan A. Alfheim, Board Chair
Cell: +47 46 44 00 45
Email: [email protected] 

or

Karin Gilljam, CEO
Cell: +47 91 80 98 87
Email: [email protected] 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/regenics-as/r/regenics-as-completes-second-tranche-of-private-placement-to-continue-development-of-collex-,c4152815

 

View original content:https://www.prnewswire.co.uk/news-releases/regenics-as-completes-second-tranche-of-private-placement-to-continue-development-of-collex-302460333.html